Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Maintained by Founders Capital Management LLC

Paterniano Del Favero
Agosto 2, 2017

$2.61M worth of stock was sold by WISNER FRANK G on Monday, March 27. With 160,900 avg volume, 19 days are for Mercury General Corporation (NYSE:MCY)'s short sellers to cover MCY's short positions. The SI to Regeneron Pharmaceutical Incorporated's float is 3.68%. The lowest price the stock reached in the last trading day was $21.56 and compares with the $18.41 52-week low. About shares traded. Walter Investment Management Corp (NYSE:WAC) has declined 63.57% since August 1, 2016 and is downtrending. It has underperformed by 10.09% the S&P500.

Among 6 analysts covering Walter Investment Management Corp (NYSE:WAC), 0 have Buy rating, 3 Sell and 3 Hold. Therefore 71% are positive. No fewer than four brokerage firms have lowered their price targets as a result, with the lowest mark coming in at $10 from RBC. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $412.00 to $421.00 and issued the company a "hold" recommendation in a study on Mon, May 15th. crowd sourced stock rating company Vetr cut Regeneron Pharmaceuticals from a "strong-buy" recommendation to a "buy" recommendation and fixed a $408.86 PT for the a note on Mon, Apr 24th. UBS AG set a $489.00 price target on Regeneron Pharmaceuticals and gave the stock a "buy" rating in a report on Friday, May 5th. The firm has "Neutral" rating given on Thursday, February 16 by Goldman Sachs. The firm has "Outperform" rating by RBC Capital Markets given on Thursday, November 5. Chardan Capital Markets has "Neutral" rating and $565 target.

7/14/2017-Credit Suisse Group was Downgraded by analysts at Credit Suisse Group from a "Hold" rating to a " rating. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since August 1, 2016 and is uptrending. Fiera Capital reported 0.02% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). The stock has "Equal Weight" rating by Barclays Capital on Wednesday, August 5.

Today, Piper Jaffray Companies reiterated its Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $557.00. Raymond James initiated the shares of REGN in report on Tuesday, September 1 with "Outperform" rating.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The company has market cap of $50.14 billion. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. It has a 57.14 P/E ratio. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Since March 29, 2017, it had 1 buying transaction, and 8 insider sales for $42.35 million activity. BROWN MICHAEL S had sold 3,000 shares worth $1.35M. Sanofi had bought 136,050 shares worth $65.06 million. The fund owned 1,461 shares of the biopharmaceutical company's stock after selling 226 shares during the period. GOLDSTEIN JOSEPH L sold $482,550 worth of stock.

Regeneron Pharmaceuticals (REGN) traded down 3.99% during trading on Friday, reaching $472.00.

Analysts expect Douglas Dynamics Inc (NYSE:PLOW) to report $0.49 EPS on August, 7.They anticipate $0.22 EPS change or 30.99% from last quarter's $0.71 EPS. REGN's profit will be $283.77 million for 46.03 P/E if the $2.67 EPS becomes a reality.

Manning & Napier Advisors LLC reduced its stake in Regeneron Pharmaceuticals, Inc. Its up 0.10, from 1.06 in 2016Q3.

On 6/16/2017 Robert J Terifay, EVP, sold 21,147 with an average share price of $468.19 per share and the total transaction amounting to $9,900,813.93. 60 funds opened positions while 188 raised stakes. Analysts predict that Regeneron Pharmaceuticals will post $12.80 EPS for the current fiscal year. Wendell David Associates Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $204,000. RMB Capital Management upped its stake in Regeneron Pharmaceuticals by 5.4% in the Q4. Lombard Odier Asset Management (Europe) Limited invested 0.13% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Meeder Asset Mgmt owns 617 shares or 0% of their U.S. portfolio. Westpac Banking holds 4,741 shares. Palisade Capital Mgmt Lc Nj reported 2,300 shares stake. Moreover, Concert Wealth Management has 0.06% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Colony Ltd Liability Corporation invested 0.03% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). First Manhattan Comm has invested 0% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Geode Capital Management Lc invested 0.23% in EOG Resources Inc (NYSE:EOG). State Street Corporation stated it has 3.24 million shares or 0.11% of all its holdings.

Altre relazioni OverNewsmagazine

Discuti questo articolo